# Vivani Medical, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Vivani Medical, Inc.). ## Overview Vivani Medical, Inc. is a U.S.-based biopharmaceutical company focused on miniature, ultra long-acting drug implant programs and related delivery platforms. The company also holds neuromodulation assets through its subsidiary Cortigent, which was formed from legacy Second Sight Medical Products and is being positioned as a separate business. ## Products & services • Miniature, ultra long-acting drug implant programs • NPM-115 GLP-1 implant candidate for weight management • NPM-119 exenatide implant program for type 2 diabetes • NPM-139 semaglutide implant program • Cortigent neurostimulation systems for body-function recovery - **Drug implant programs** (70%) — Preclinical and clinical-stage miniature implants designed to deliver GLP-1 therapies over long durations. - **Metabolic disease candidates** (20%) — Implant-based therapies aimed at obesity, overweight, and type 2 diabetes indications. - **Neurostimulation systems** (10%) — Brain implant and neuromodulation assets intended to help patients recover critical body functions. - Miniature, ultra long-acting drug implant programs - NPM-115 GLP-1 implant candidate for weight management - NPM-119 exenatide implant program for type 2 diabetes - NPM-139 semaglutide implant program - Cortigent neurostimulation systems for body-function recovery ## Customers Vivani does not sell commercial products broadly today; its direct counterparties are primarily clinical investigators, research partners, regulators, and contract development and manufacturing organizations that support product development. The eventual end customers for its implant programs are patients with chronic metabolic diseases, while Cortigent’s technologies are aimed at patients with severe neurological impairment or loss of function. - **Clinical development partners** (primary) — CROs, trial sites, and manufacturers that support preclinical and clinical testing of implant candidates. - **Metabolic disease patients** (primary) — People with obesity, overweight, or type 2 diabetes who are the intended users of GLP-1 implant therapies. - **Neuromodulation patients** (secondary) — Patients with severe neurological conditions who may benefit from Cortigent's implantable systems. - **Regulatory stakeholders** (primary) — FDA and other regulators that determine whether programs can advance into and through clinical development. - Clinical trial participants in obesity, overweight, and diabetes studies - Patients with chronic metabolic disease as the eventual end users - Neurology and rehabilitation patients targeted by Cortigent systems - Regulators and ethics bodies that govern development and testing - CROs, manufacturers, and research partners supporting trials ## Geography Vivani is headquartered in the United States and operates as a development-stage company with U.S.-based corporate and regulatory activity. It also established Vivani Medical Australia Pty Ltd. to support studies of its product candidates, reflecting a small but important international clinical footprint. - **United States** (90%) — Primary corporate, development, and regulatory base - **Australia** (10%) — Supports studies of product candidates - United States is the main corporate and regulatory base - Clinical and development work is centered on U.S. programs - Australia supports studies of product candidates - Geography matters because trial location affects approvals and timelines - No country revenue disclosure is provided in the excerpts ## Strategy Vivani's strategy centers on advancing its miniature drug implant platform, with NPM-115, NPM-119, and NPM-139 representing the core metabolic pipeline. In parallel, the company is working to separate Cortigent into an independent public company so each business can pursue its own therapeutic focus and capital strategy. - **Advance lead metabolic implant programs** (short-term) — Clinical progress is the main value driver for a development-stage company. - **Separate Cortigent into a standalone company** (short-term) — A spin-off can create two more focused businesses with distinct capital needs and strategies. - **Build a broader long-acting implant portfolio** (medium-term) — A platform approach can extend the technology beyond a single lead asset. - Advance the miniature ultra long-acting implant platform - Prioritize GLP-1 programs for obesity and diabetes - Progress NPM-139 as a semaglutide implant candidate - Support Cortigent separation into an independent company - Use focused capital allocation across two therapeutic areas ## Risks Vivani faces the typical risks of a development-stage biotech company: heavy dependence on external financing, uncertain clinical outcomes, and regulatory delays. Its dual-track structure also adds execution risk because the company must advance metabolic implants while managing the separation of Cortigent and the associated legal, tax, and listing approvals. - **Additional financing requirement** [high] — Development programs consume cash before any product revenue exists, so funding access is critical. - **Clinical development uncertainty** [high] — Preclinical and clinical programs can fail on safety, efficacy, or pharmacokinetics. - **Regulatory delay or hold** [high] — FDA or other regulators can pause, narrow, or delay studies and commercialization. - **Cortigent spin-off execution** [medium] — The separation requires SEC, Nasdaq, tax, and board approvals and could be delayed or fail. - **Third-party dependence** [medium] — CROs, manufacturers, and study sites affect trial quality, timing, and cost. - Needs substantial additional financing to fund development - Clinical trials may fail, be delayed, or require redesign - Regulatory holds or approvals can materially affect timelines - Spin-off execution risk for Cortigent could disrupt focus - Reliance on third parties creates manufacturing and trial risk ## Accounting As a development-stage biotech, Vivani's reported results are driven mainly by research and development and general and administrative expense rather than product revenue. Investors should watch estimates tied to stock-based compensation, grant offsets, and any valuation or impairment judgments related to subsidiary structures and development assets. - **Research and development expense** — Clinical progress changes quarterly expense levels - **Stock-based compensation** — Can materially affect G&A and R&D expense - **Grant accounting** — Offsets development spend and affects comparability - **Consolidation and spin-off accounting** — Spin-off timing can change reported structure and balances - R&D and G&A expense recognition drives reported operating losses - Stock-based compensation is a non-cash expense estimate - Grant proceeds may reduce operating expenses when recognized - Subsidiary and spin-off structures can affect consolidation and valuation - Development-stage assets may require impairment or fair value review --- *Last updated: 2026-04-29T05:08:31.485047+00:00*